n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, December 30th, 2015

The QualityStocks
Daily Stock List

graphic
graphic

Pacific Office Properties Trust, Inc. (PCFO)

TopPennyStockMovers and Real Pennies reported on Pacific Office Properties Trust, Inc. (PCFO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pacific Office Properties Trust, Inc. is a real estate investment trust (REIT) whose shares trade on the OTC Markets Group’s OTCQB. The Company is an externally advised REIT that owns and operates principally institutional-quality office properties in the State of Hawaii. Pacific Office Properties Trust has its corporate head office in Honolulu, Hawaii.

The Company owned three office properties as of September 30, 2015, consisting of 1.2 million rentable square feet. In addition, it was partners with third parties in three joint ventures, holding two office properties consisting of four buildings and 0.8 million rentable square feet.

One of Pacific Office Properties Trust’s joint ventures also owns a sports club associated with the Company’s City Square property (Central Business District/North Central) in Phoenix, Arizona. Its ownership interest percentage in each of these joint ventures is 5.0 percent.

The Company’s Property Portfolio included office buildings in Honolulu and Phoenix, as of September 30, 2015. Pacific Office Properties Trust receives income chiefly from rental revenue (including tenant reimbursements) from its office properties and, to a lesser extent, from its parking revenues. Its office properties are normally leased to tenants with good credit for terms ranging from two to 20 years.

As of September 30, 2015, Pacific’s wholly-owned properties were 87.0 percent leased, with around 145,800 square feet available, under a total of 329 leases. As of that date, 6.5 percent of the Company’s leased square footage was scheduled to expire during this year. In addition, another 12.7 percent of its leased square footage was scheduled to expire during 2016.

The Company’s properties in Honolulu include the Davies Pacific Center (Central Business District); the Pacific Business News Building (Kapiolani); the Pan Am Building (Kapiolani) as well as the Waterfront Plaza (Central Business District).

Pacific Office Properties Trust’s advisor is Shidler Pacific Advisors, LLC. This is an entity owned and controlled by Mr. Jay H. Shidler, Pacific’s Chairman of the Board. Shidler Pacific Advisors is responsible for the day-to-day operation and management of the Company. This includes management of its wholly-owned properties.

Pacific Office Properties Trust, Inc. (PCFO), closed Wednesday's trading session at $0.85, even for the day, on 8,040 volume with 13 trades. The average volume for the last 60 days is 2,748 and the stock's 52-week low/high is $0.06/$1.00.

Mikros Systems Corp. (MKRS)

Fast Money Alerts, PricelessPennyStocks, Actual Gains, PennyStockRumors.net, and AddictivePennyStocks reported earlier on Mikros Systems Corp. (MKRS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Mikros Systems Corp. is an advanced technology company based in Princeton, New Jersey. It designs and manufactures specialized electronic systems for the Department of Defense. Its primary business is to pursue and obtain contracts from the Department of Homeland Security, the U.S. Navy, and other governmental authorities. Mikros has developed, delivered, and installed military-grade equipment to Federal customers for more than three decades. The Company lists on the OTC Markets’ OTCQB.

Mikros Systems’ capabilities include technology management, electronic systems engineering and integration, radar systems engineering, command, control, communications, computers and intelligence systems engineering, and communications engineering.

The Company has required processes in place for the handling, accounting, storage and control of classified material. The majority of its employees are cleared for classified information knowledge. Mikros’ Lifecycle Support capability is centered on ensuring the systematic interactions between Integrated Logistics Support (ILS), Depot, and Field Support activities are integrated to realize the highest levels of system readiness.

Mikros Systems has purchased certain software products, intellectual property (IP) and related assets from VSE Corp. The primary software programs purchased by Mikros are the Prognostics Framework (PF) and Diagnostic Profiler (DP) programs. The Diagnostic Profiler software is used around the world by several multinational companies for optimized maintenance of diverse product lines.

Additionally, Diagnostic Profiler is used by the U.S. Air Force for depot test programs. Prognostics Framework is used by the U.S. Army for a number of missile defense systems. These new software products provide Mikros Systems with the opportunity to service commercial customers and additional Department of Defense customers outside the Navy.

In November, Mikros Systems announced its financial results for Q3 and nine-month period ended September 30, 2015. It reported considerable increases in revenue for Q3 and the first nine months of 2015. Third quarter revenues were $1,240,393. This represents an increase of $182,951 or 17 percent from the comparable year ago period.

For the first nine months of 2015, it reported revenues of $5,450,815 versus $3,150,584 during the corresponding period of 2014. This represents an increase of $2,300,231 or 73 percent. Year to date, Mikros Systems reported net income of $298,238, an increase of $48,554 or 19 percent versus 2014. Net income for Q3 was $36,736 versus net income of $127,435 during Q3 of 2014.

Mikros Systems Corp. (MKRS), closed Wednesday's trading session at $0.125, down 2.34%, on 52,689 volume with 9 trades. The average volume for the last 60 days is 18,890 and the stock's 52-week low/high is $0.0831/$0.1801.

RealBiz Media Group, Inc. (RBIZ)

SmallCapVoice, TopPennyStockMovers, Stock Commander, and Juicy Penny Stocks reported earlier on RealBiz Media Group, Inc. (RBIZ), and we also choose to report on the Company, here at the QualityStocks Daily Newsletter.

RealBiz Media Group, Inc. is a real estate digital media and technology enterprise. The Company’s proprietary video processing technology makes it one of the leaders in providing home video tours to the real estate industry. Its customer base includes over 350,000 real estate agents and brokers. RealBiz Media Group is headquartered in Fallbrook, California.

The Company provides a series of products including a consumer portal www.nestbuilder.com, an agent-only platform called PowerAgent, an agent social media and marketing solution called ReachFactor, a growing MVA network, virtual tours, and mobile apps. RealBiz Media Group has access to the nation’s largest real estate companies with many approved vendors and national contracts.

Its strength is focused on its proprietary video production and distribution technology. RealBiz’s proprietary technology allows the automated conversion of data, including text and pictures of home listings, into video with voice and music. Upon creation, the videos can automatically be distributed to multiple media platforms for consumer viewing. The Company, with the move to automated creation processes in combination with emerging video adoption, now develops custom enterprise solutions to support existing and new franchise partners.

RealBiz Media Group acquired ReachFactor, Inc. in 2014. ReachFactor is a social media marketing platform. It helps real estate agents and brokerages grow their online visibility, connect with customer prospects, and turn those prospects into new customers. This acquisition adds depth to RealBiz Media Group's agent products, brings thousands of agent subscribers, and expands the Company’s ability to market its services directly to highly engaged real estate agents.

In 2014, RealBiz launched Nestbuilder.com, the Agent MVA marketing Platform, ezflix and Nestbuilder apps in the Android version. Rounding out the product lineup will be its introduction of the IOS versions of Nestbuilder and ezflix and the introduction of the Home and Away Club rewards programs for agents and consumers. The ezflix app is the only mobile app available to real estate agents that pre-integrates property listings from multiple listing services. This is so agents can then create and customize digital material including video, mini commercials, neighborhood tours and community events to provide prospective buyers more contexts about every listing.

Recently, RealBiz Media Group announced that it would be offering clients a free upgrade of its new high definition product. RealBiz produces more than 15,000 videos daily. It has in place exclusive agreements with key players such as Century21 and ERA systems.

The RealBiz video platform is constructed on 20 patents and developed completely in house over 10 years. It is the premier video technology platform for high speed, high quality video production. RealBiz Media Group announced that every client will now be upgraded to a high definition format giving each video 1280-pixel resolution and a high bit rate.

RealBiz Media Group, Inc. (RBIZ), closed Wednesday's trading session at $0.04, down 19.84%, on 385,200 volume with 22 trades. The average volume for the last 60 days is 85,001 and the stock's 52-week low/high is $0.0219/$0.39.

Neurotrope, Inc. (NTRP)

SmallCapVoice reported recently on Neurotrope, Inc. (NTRP), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Neurotrope, Inc. is a specialty biopharmaceutical company based in Newark, New Jersey. Neurotrope Bioscience, Inc. is the operating subsidiary of Neurotrope, Inc. Neurotrope Bioscience was formed in October 2012 primarily to license, develop, and commercialize various novel therapeutic and diagnostic technologies from the Blanchette Rockefeller Neuroscience Institute (BRNI) focused on the development of conventional small molecules that are extraordinarily potent in the activation of the enzyme PKCe. Neurotrope’s shares trade on the OTCQB.

The scientific basis of the Company’s treatment is activation of Protein Kinase C isozymes ε and α by bryostatin, a natural product that can result in enhancement of existing synapses, reduces toxic amyloid generation, promotes synaptogenesis, and enhances memory and learning, therefore having the potential to improve cognitive function in Alzheimer's disease. Neurotrope has started its Phase 2b clinical trial in 150 moderately severe to severe Alzheimer's patients.

Additionally, the Company is conducting preclinical studies of bryostatin as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease. These are two rare genetic diseases for which only symptomatic treatments are presently available. The Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neurotrope for bryostatin as a treatment for Fragile X Syndrome.

Neurotrope has exclusive licensed technology from the Blanchette Rockefeller Neurosciences Institute for Alzheimer's disease and Fragile X Syndrome, has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease and is partnered with Stanford University to synthesize and find the next generation bryostatin – called bryologs.

In June 2015, Neurotrope announced that Neurotrope Bioscience would conduct a preclinical study, in collaboration with a foremost research institution, to examine the effect of bryostatin in Niemann-Pick type C (NPC) mice. The financing of the study is by a number of family foundations under the auspices of Support Of Accelerated Research for NPC Disease (SOAR-NPC).

Last month, Neurotrope announced that it entered into definitive agreements to sell its securities in a private placement. The Company will use the proceeds from the private placement to chiefly fund its Phase 2b clinical trial in 150 moderately severe to severe Alzheimer's disease patients and provide working capital.

Neurotrope, Inc. (NTRP), closed Wednesday's trading session at $0.50, down 1.96%, on 17,779 volume with 7 trades. The average volume for the last 60 days is 12,947 and the stock's 52-week low/high is $0.40/$1.79.

Global Future City Holding, Inc. (FTCY)

TopPennyStockMovers reported previously on Global Future City Holding, Inc. (FTCY), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Global Future City Holding, Inc. is a holding company with corporate headquarters in Mission Viejo, California. It concentrates on implementing an EB-5 immigrant investor program for foreign investors who are interested in acquiring lawful permanent residence in the United States and the marketing and deployment of its MLM loyalty-based retail program. The Company previously went by the name FITT Highway Products, Inc. It changed its name to Global Future City Holding, Inc. in October 2014. As of April 17, 2015, Global Future City Holding operates as a subsidiary of Sky Rover Holdings Ltd.

The Company’s intention is to focus its first efforts on acquiring qualified investment projects aligned with the acquired EB-5 Regional Center and launching the digital security-based MLM program with an impending registered digital currency. Global Future City Holding, via its acquisition of Powerdyne, is implementing the above-mentioned EB-5 immigrant investor program. Under the program, Company Management’s intention is to pool EB-5 capital from foreign investors for the purpose of acquiring qualified investment projects meeting the requirements of the EB-5 program.

Recently, the Company announced a change in its future business plans. It had previously centered on integrating the crypto-asset, E-Gold (EGD), into its business plan by requesting a No-Action position by the Securities Exchange Commission (SEC). On October 9, 2015, it announced the withdrawal of the Request for No-Action Relief Letter. It decided that it would not proceed with the proposed activities outlined in the Letter. Global Future City Holding announced the closing of the EGD Spinoff.

Global Future City Holding also involves in the energy shot business. It provides three energy shots to the retail market. It markets two-ounce energy shots under the F.I.T.T. Energy For Life, F.I.T.T. Extreme Energy For Life, and F.I.T.T. RX For Life names. The Company also focuses on marketing the FITT product line under strategic market alliances in China and South America markets. It will continue to market and sell its F.I.T.T. brand of energy drinks to domestic and international markets, incorporating the reward program through giving away a registered crypto-asset currency other than EGD with the purchase of its products.

Last week, Global Future City Holding announced that its wholly-owned subsidiary, GX-Life Global, Inc., would expand its signature multi-level marketing (MLM) program to Chinese distributors with support from strategic partner Global Access, a top provider of cross-border e-commerce technology and shipping solutions.

Mr. Ning Liu, CEO and President of Global Future City Holding, said, “In recent years, direct selling in China has grown almost three times faster than the global average, heightening a need for stable digital assets in the country. We believe that GX-Coins, the digital currency at the heart of GX-Life Global’s ecommerce platform, provide an exciting and secure way for consumers in China to participate in the global marketplace, obtaining goods and services that would be otherwise unavailable to them and benefitting economies around the world.”

Global Future City Holding, Inc. (FTCY), closed Wednesday's trading session at $2.83, up 13.20%, on 2,199 volume with 5 trades. The average volume for the last 60 days is 12,767 and the stock's 52-week low/high is $0.20/$3.48.

graphic

The QualityStocks
Company Corner

graphic
graphic

Nutra Pharma Corp. (NPHC)

The QualityStocks Daily Newsletter would like to spotlight Nutra Pharma Corp. (NPHC). Today, On the Move Systems, Inc. closed trading at $0.055, up 4.36%, on 287,575 volume with 25 trades. The stock’s average daily volume over the past 60 days is 227,894, and its 52-week low/high is $0.0025/$0.27.

Nutra Pharma Corp. announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website. "We have had a very busy year at Nutra Pharma," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "2015 has been an inflection year for the company, launching our first new product in over two years (Pet Pain-Away), allowing us to begin to get back into clinical research on our lead drug candidates and bringing our drug platform into focus with the granting of Orphan designation for RPI-78M for the treatment of pediatric multiple sclerosis," he continued. "I wanted to take this opportunity to update our shareholders and the public on the accomplishments of the year, the status of the Company and briefly outline our goals and expectations for the coming months," he concluded.

Nutra Pharma Corp. (NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.

The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain. The subsidiary also provides small and start-up biotech companies a full range of contract research services through its ISO class 5 and GMP certified facilities in Plantation, Florida.

Nutra Pharma recently received Orphan Drug Status from the FDA for the treatment of pediatric MS for its drug, RPI-78M. The designation of RPI-78M as an Orphan Drug provides Nutra Pharma with a seven-year period of market exclusivity in the U.S. once the drug is approved. Additional benefits over conventional drug applications include: tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, plus assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The granting of Orphan Drug Designation allows Nutra Pharma to move forward with its preparation of an Investigative New Drug Application and proposal of clinical trials. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.

ReceptoPharm holds all of the intellectual property for Nutra Pharma's drug pipeline, while Nutra Pharma directly holds all of the property dealing with their over-the-counter drugs. This includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company's Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Nutra Pharma is a revenue-generating company with 12 patents and patents pending, three completed phase 1/phase 2 clinical trials, and 12 FDA-registered OTC products in the United States. The company also has regulatory clearance for Nyloxin in India, where management believes its initial distribution streams could become the company's biggest market. Management is also defining its plan to expand into China and Canada while strengthening its position the United States. Disclaimer

Nutra Pharma Corp. Company Blog

Nutra Pharma Corp. News:

Nutra Pharma CEO, Rik J Deitsch, Has Published a Letter to Shareholders Outlining the Current Efforts and the Future Goals of the Company

Nutra Pharma Corp. (NPHC) CEO Featured in Exclusive QualityStocks Interview

Nutra Pharma Corp. (NPHC) Announces Engagement of QualityStocks Corporate Communications Suite

Alternet Systems, Inc. (ALYI)

The QualityStocks Daily Newsletter would like to spotlight Alternet Systems, Inc. (ALYI). Today, Alternet Systems, Inc. closed trading at $0.0094, up 56.67%, on 469,897 volume with 14 trades. The stock’s average daily volume over the past 60 days is 155,594, and its 52-week low/high is $0.0055/$0.045.

Alternet Systems, Inc. (ALYI) invests in and partners with companies that are creating the future of money in the high growth, emerging technology fields of digital commerce, multichannel payments, and predictive analytics.

Vision: Be the leading digital commerce, multichannel payments, predictive analytics solutions provider into global markets

Mission: To provide innovative solutions that facilitates and expedites commerce, enriching our partners and their customers' experience, and improving efficiency. Recognizing that the world is becoming increasingly dependent on technological conveniences, Alternet Systems aims to provide its customers with the tools to prepare themselves for a new era of digital commerce and payments, financial services and consumer information, and, most importantly, a new era of how to live.

Since 2010, Alternet has maintained a progressive focus on the high-growth, mobile value-added service industries of mobile financial services and mobile security. In 2014, the company expanded its scope of expertise to include in its investment verticals the exciting digital commerce space, transforming the legacy electronic payments infrastructure and developing advanced predictive data analytics applications for the mass consumer, telecommunications and financial industry.

With strategic investments in these three key, high-growth markets, Alternet is accelerating the future of money and its role in the global demand for these services. The company is guided by a team of executives specializing in entrepreneurial endeavors, innovation, corporate strategy, financial and executive management of multi-national organizations, and a vast network of industry resources.

As Alternet embarks on this new path, the company will be led by a management team and board of directors with over a century's worth of combined experience in the fields of investing, technology, and financing, and the consensus knowledge of where to invest and when in start-up and early-stage companies. Disclaimer

Alternet Systems, Inc. Company Blog

Alternet Systems, Inc. News:

Alternet Systems (ALYI) CEO Featured in Exclusive QualityStocks Interview

Alternet Payment Solutions Offers Disruptive Omni-Channel Payment Processing Technology in the U.S.

Alternet Systems Appoints Fabio Alvino as CEO of Alternet Payment Solutions

Cherubim Interests, Inc. (CHIT)

The QualityStocks Daily Newsletter would like to spotlight Cherubim Interests, Inc. (CHIT). Today, Cherubim Interests, Inc. closed trading at $0.0003, up 50.00%, on 6,830,200 volume with 7 trades. The stock’s average daily volume over the past 60 days is 55,808,581, and its 52-week low/high is $0.0001/$0.33.

Cherubim Interests, Inc. (CHIT) is a development-stage alternative construction and real estate development company seeking various opportunities relative to the company's management team of experts in property management, construction and finance.

The company's primary focus is within the real estate development and controlled environment agriculture sectors, which Cherubim recently entered into by acquiring an exclusive worldwide license for the deployment of a proprietary plant cultivation technology. Through its wholly owned subsidiary, BudCube Cultivation Systems USA, Cherubim plans to construct, deploy and lease scalable medical and recreational marijuana cultivation facilities for commercial applications.

Coupled with a real estate development and property management business model, BudCube Cultivation Systems ("BCS") can position itself anywhere in the world where the cultivation of cannabis is legal. BCS's unique business model positions the company to greatly benefit as more market participants seek to gain entry into a fast-growing market at an attractive price point.

Armed with the ability to lease a portable and scalable turn-key cultivation solution to growers, Cherubim aims to use its licensed solution to fill the gap for both first-time and experienced cultivators who may not have the capital resources to buy land, construct or tenant-improve existing structures for the optimum environment for developing a high-quality cannabis product. Disclaimer

Cherubim Interests, Inc. Company Blog

Cherubim Interests, Inc. News:

Cherubim Interests, Inc. Adds Powerhouse VP

Cherubim Interests, Inc. Announces End of Year Convertible Preferred Stock Dividend

Cherubim Interests (CHIT) Signs MOU With United Cannabis Corp. (CNAB)

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $3.30, up 0.61%, on 31,919 volume with 79 trades. The stock’s average daily volume over the past 60 days is 18,361, and its 52-week low/high is $1.25/$11.625.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.

The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.

In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health

International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson's Disease

International Stem Cell Corporation Announces Launch Plans for New Nano-Compound Products

Legacy Ventures International, Inc. (LGYV)

The QualityStocks Daily Newsletter would like to spotlight Legacy Ventures International, Inc. (LGYV). Today, Legacy Ventures International, Inc. closed trading at $1.69, up 1.81%, on 76,665 volume with 126 trades. The stock’s average daily volume over the past 60 days is 30,153, and its 52-week low/high is $0.01/$2.50.

Legacy Ventures International, Inc. (LGYV) is an investment company seeking out high-potential businesses with big ideas that can be scaled in order to promote hyper growth. The company fuels innovation and passion by providing the capital, oversight and connections that young businesses need to reach their full potential.

Legacy is led by a highly-qualified executive team with decades of relevant industry experience. Evan Clifford, the company's chief executive officer, has spent more than 15 years building and maintaining relationships with some of North America's most influential executives. Over the past decade, he has served as a lead advisor to a collection of companies and individuals striving for personal and professional success. Likewise, Rehan Saeed, Legacy's chief financial officer, has over a decade of experience in the banking industry during which he built and managed a real estate portfolio valued at $110 million.

The company's current brand portfolio is headlined by newly-acquired RM Fresh Brands, a servicer of food and beverage retailers and distributors around the globe. RM Fresh Brands takes a unique approach to brand partnerships by maintaining a clear focus on sustainable, category-changing consumables. This strategy has helped it build an extensive portfolio of highly-desirable brands – including Boxed Water, Aloe Gloe, Uncle Si's Iced Tea and Chef 5-Minute Meals.

Following the successful acquisition of RM Fresh Brands, Legacy is in a strong strategic position to move forward with its efforts to promote sustainable growth. The company will lean on the considerable experience of its management team as it looks to build on its recent progress while promoting maximized shareholder value. Disclaimer

Legacy Ventures International, Inc. Company Blog

Legacy Ventures International, Inc. News:

Legacy Ventures Welcomes G. Scott Paterson to the Advisory Committee

Legacy Ventures International Due Diligence Report: Being Green is in; Boxed Water a Step Closer to Reducing the Carbon Footprint

Legacy Ventures Subsidiary RM Fresh Brands Completes Agreement to Supply Products to Sysco for Distribution

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

QualityStocks
(ALYI)

2.

Tip.us
(CHIT)

3.

Financials Trend
(URRE)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251